Our Leadership Team

Executive Director, Information Technology, Personalized Medicine

Samuel "Sandy" Aronson is the Executive Director of IT and AI Solutions for Mass General Brigham Personalized Medicine and the Senior Director of IT for our Accelerator for Clinical Transformation. His teams develop and deploy technology to improve clinical processes in clinical genetics, remote health and decentralized clinical trials. In clinical genetics, the team has built infrastructure that supports the evolution and practice of genetic based personalized medicine in both patient facing and laboratory settings. This system ecosystem enables a continuous learning process that harnesses clinical testing flows to advance knowledge surrounding genetic variation. The infrastructure includes the GeneInsight Suite of applications that were registered as a medical device and distributed. The team is now working to deepen support for whole genome sequence management and interpretation. This includes developing and validating Generative AI functionality to support variant assessment.

The team has also deployed a platform that enables remote patient management by task shifted workforces using omnichannel communication. These capabilities have been used to equitably manage large patient populations. The platform is also currently supporting multiple decentralized clinical trials. We are now enhancing these capabilities using Generative AI focused on improving trial quality and cost effectiveness.

Prior to this position, Mr. Aronson was an IT consultant to the biotechnology industry working for Tribiosys. Mr. Aronson also held several positions with Sapient Corporation, was a Strategic Consultant for Monitor Company and founded both LearningAction, a web-based training company now part of Best Software and Stanford Data Solutions, a software consulting firm. Mr. Aronson holds a Masters in Organizational Behavior and a Bachelors in Computer Science from Stanford University. He also holds a Masters focused in Biology from Harvard Extension School.

Program Director, Biobank, Personalized Medicine
Director, Information Technology, Personalized Medicine

Natalie Boutin is program director at the Biobank and director of IT at Personalized Medicine. In this dual capacity, she is responsible for the Biobank’s operations and for its information technology infrastructure. She also oversees systems that drive clinical and research genomics at Personalized Medicine.

Director, Bioinformatics, Personalized Medicine
Director, Laboratory for Molecular Medicine, Personalized Medicine
Associate Professor, Pathology, Brigham and Women's and Harvard Medical School

Dr. Lebo joined Personalized Medicine as an assistant laboratory director for the Laboratory for Molecular Medicine in 2011 after completing his ABMG molecular genetics fellowship training at the Harvard Medical School Genetics Training Program. In the fall of 2013, Dr. Lebo became the head of Bioinformatics at Personalized Medicine and associate laboratory director for the Laboratory for Molecular Medicine. In 2018, he become the director of the Laboratory for Molecular Medicine.

Director, Clinical Laboratory Operations, Personalized Medicine

Lisa Mahanta is the director of Clinical Laboratory Operations for Personalized Medicine. She oversees laboratory operations for Personalized Medicine, including the Laboratory for Molecular Medicine. She received her bachelor’s degree from the University of New Hampshire in 2000 in biology with a minor in genetics. With the center since 2005, Lisa focuses on streamlining operations and implementing solutions that reduce labor, cost, and turnaround time while improving and maintaining quality. This paradigm continues as the landscape of molecular testing continues to be both complex and dynamic.

Associate Laboratory Director, Laboratory for Molecular Medicine, Personalized Medicine
Instructor, Pathology, Brigham and Women's Hospital

Dr. Mason-Suares joined Personalized Medicine in 2014 as an associate laboratory director at the Laboratory for Molecular Medicine and assistant director to the Molecular Genetics ABMG Fellowship, part of the Harvard Medical School Genetics Training Program.

Director of Preventive Cardiology, Massachusetts General Hospital
Paul and Phyllis Fireman Endowed Chair in Vascular Medicine, Massachusetts General Hospital
Associate Director of Personalized Medicine, Mass General Brigham
Associate Professor of Medicine, Harvard Medical School
Associate Member, Broad Institute of Harvard and MIT

Dr. Pradeep Natarajan is the Associate Director of Personalized Medicine at Mass General Brigham, Director of Preventive Cardiology at Massachusetts General Hospital, and Associate Professor of Medicine at Harvard Medical School. As a principal investigator within the Cardiovascular Research Center at Massachusetts General Hospital, the Program in Medical and Population Genetics at the Broad Institute, and Harvard Medical School, he leads an interdisciplinary research group using emerging methods in biomedical informatics and human investigation to leverage naturally occurring human genetic variation to advance the prevention of cardiovascular diseases, particularly atherosclerotic cardiovascular disease. He is a recognized investigative and clinical leader in the combined germline and somatic genetic basis of atherosclerotic cardiovascular disease leading several research consortia and advancing novel clinical precision cardiovascular medicine paradigms.

Sr. Administrative and Financial Director, Personalized Medicine

Meini Shin is the senior administrative and financial director for Personalized Medicine. She oversees the overall operation of the center, human resources, financial planning, budgeting, grant management, and all financial services including accounting, payroll, and procurement. She supports the scientific director on strategic initiatives. Meini’s background includes over 20 years of experience in financial management, planning, and budgeting. 

Co-Investigator, Mass General Brigham Biobank, Personalized Medicine
Scientific Director, Mass General Research Institute
Professor, Neurology, Massachusetts General Hospital

Dr. Slaugenhaupt , is the Scientific Director of the Mass General Research Institute, a strategic initiative that will support the entire research enterprise at Mass General to foster and sustain medical innovation. She is also a Professor in the Department of Neurology at Mass General and Harvard Medical School, and an Investigator in the Center for Genomic Medicine. She also co-directs the Mass General Brigham Biobank at Mass General, an exciting initiative that will speed the translation of research discoveries into improved clinical care for patients.

Dr. Slaugenhaupt spearheads several programs and educational initiatives at Mass General, including a thriving undergraduate summer internship program. Her Research Institute team works to promote science at Mass General by increasing interactions with industry, by fundraising for Research Institute initiatives, including partnering with individual philanthropists, their families and foundations and by promoting Mass General research to the community through events and social media.

Dr. Slaugenhaupt's research focuses on two neurological disorders, familial dysautonomia (FD) and mucolipidosis type IV (MLIV), as well as the common cardiac disorder mitral valve prolapse (MVP). Discoveries in Dr. Slaugenhaupt’s laboratory have led to the successful implementation of critical population screening for FD and MLIV, and to the development of a treatment for FD that directly targets the mRNA splicing mechanism. This exciting work has led to a clinical trial of the first therapeutic for FD aimed at altering the molecular defect.

In 2013, Dr. Slaugenhaupt was named the Elizabeth G. Riley and Dan E. Smith, Jr. MGH Research Scholar. In 2016, she was honored with a prestigious Javits Neuroscience Investigator Award by the National Institute for Neurological Disorders and Stroke (NINDS) at NIH, and she was recently named one of the 2016 Top Ten Women to Watch in Science and Technology by the Boston Business Journal. In 2020, she was named the Elizabeth G. Riley and Daniel E. Smith, Jr. Endowed MGH Research Institute Chair.

Co-Investigator, Mass General Brigham Biobank, Personalized Medicine
Professor, Psychiatry, Massachusetts General Hospital

Dr. Jordan Smoller is the MGH Trustees Endowed Chair in Psychiatric Neuroscience, Professor of Psychiatry at Harvard Medical School and Professor in the Department of Epidemiology at the Harvard School of Public Health in Boston. He is Associate Chief for Research in the Massachusetts General Hospital (MGH) Department of Psychiatry and Director of both the Psychiatric and Neurodevelopmental Genetics Unit and the Precision Medicine Research Unit in the MGH Center for Genomic Medicine. Dr. Smoller is a Tepper Family MGH Research Scholar and also serves as Director of the Omics Unit of the MGH Division of Clinical Research and co-Director of the Partners HealthCare Biobank at MGH. He is an Associate Member of the Broad Institute and a Senior Scientist at the Broad’s Stanley Center for Psychiatric Research. He is also Vice President of the International Society of Psychiatric Genetics.

He co-chairs the Cross-Disorder Workgroup of the international Psychiatric Genomics Consortium which has been examining how genetic influences transcend diagnostic boundaries. He is a PI in the Electronic Medical Records and Genomics (eMERGE) network and lead PI of the New England Precision Medicine Consortium as part of the NIH Precision Medicine Initiative’s All of Us Research Program. He is an author of more than 300 scientific publications and is also the author of The Other Side of Normal (HarperCollins/William Morrow, 2012).

Assistant Laboratory Director, Laboratory for Molecular Medicine, Personalized Medicine
Instructor, Pathology, Massachusetts General Hospital and Harvard Medical School

Dr. Zouk joined Personalized Medicine in 2016 as an assistant director at the Laboratory for Molecular Medicine after completing her ABMGG fellowship in clinical molecular genetics at the Harvard Medical School Genetics Training Program.

Dr. Zouk’s work has focused on genetic testing that combines high-throughput technologies along with advanced clinical interpretation to provide comprehensive genetic information that can be used for effective implementation in personalized medicine. She is actively involved in the end-to-end final interpretation and sign-out of clinical genetic tests, both in a diagnostic setting, and in a genomic screening environment, as a co-investigator or collaborator on various projects, where she oversees the day-to-day management of the interpretation of the genomic data and return of clinical reports to participants.